Biogen forward PE BIIB

Share price divided by analysts' consensus earnings for the next twelve months, since 1997.

Today, Oct 23, 2026: 19.1×
10-year median: 14.1×
Against its 10-year history: 90th; percentile: 0 is its lowest day, 100 its highest
10-year range: 6.9× to 24.3×
Peer median: 10.9×

Biogen's forward PE is 19.1× as of Oct 23, 2026.

That is above its ten-year median of 14.1×, higher than on 90% of days in the last ten years.

Over that time it ranged from 6.9× in Aug 2019 to 24.3× in Jun 2021.

The median for 10 large drugmakers of a similar size is 10.9×.

Forward PE over time

median 14.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	19.1×	15.3×	20.9×
2025	18.4×	9.4×	18.9×
2024	10.8×	10.5×	17.8×
2023	17.9×	15.5×	22.1×
2022	19.1×	12.3×	21.0×
2021	15.1×	13.7×	24.3×
2020	13.3×	8.7×	17.9×
2019	9.4×	6.9×	11.5×
2018	10.0×	9.6×	15.9×
2017	14.3×	12.3×	15.9×
2016	15.3×	12.4×	17.5×
2015	18.4×	16.6×	32.2×
2014	23.5×	20.8×	30.1×
2013	26.9×	21.7×	28.8×
2012	22.3×	20.5×	25.8×
2011	19.6×	11.6×	20.5×
2010	12.7×	10.4×	14.1×
2009	13.0×	10.3×	15.5×
2008	13.7×	11.5×	21.0×
2007	18.8×	16.6×	27.0×

Against its peers

Companies in Drug Manufacturers - General nearest Biogen's size, closest first, today.

Company	Forward PE
BIIBBiogen	19.1×
JAZZJazz Pharmaceuticals	n/m
BMYBristol-Myers Squibb	10.4×
BMRNBiomarin Pharmaceutical	n/m
CORTCorcept Therapeutics	n/m
PTGXProtagonist Therapeutics	n/m
TGTXTG Therapeutics	n/m
PFEPfizer	10.9×
ALKSAlkermes plc.	n/m
GILDGilead Sciences	17.2×
AMRXAmneal Pharmaceuticals	n/m
Peer median	10.9×

Where Biogen ranks

#25of 51Healthcare stocks with the lowest forward PE

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Biogen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.